<DOC>
	<DOCNO>NCT00182741</DOCNO>
	<brief_summary>RATIONALE : Calcitriol may cause prostate cancer cell look like normal cell , grow spread slowly . Drugs use chemotherapy , mitoxantrone prednisone , work different way stop growth tumor cell , either kill cell stop dividing . PURPOSE : This phase II trial study well give calcitriol together mitoxantrone prednisone work treat patient metastatic prostate cancer .</brief_summary>
	<brief_title>Calcitriol , Mitoxantrone , Prednisone Treating Patients With Metastatic Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine prostate-specific antigen ( PSA ) response rate , define fraction patient 50 % reduction PSA level 3 week ' time , patient androgen-independent metastatic prostate cancer treat high-dose pulse calcitriol , mitoxantrone , prednisone . Secondary - Determine safety tolerability regimen patient . OUTLINE : This multicenter study . Patients receive oral high dose pulse calcitriol day 1 , mitoxantrone IV day 2 , oral prednisone day 1-21 . Treatment repeat every 21 day 12 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow periodically . PROJECTED ACCRUAL : A total 48 patient accrue study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm prostate cancer Androgenindependent disease , define disease progression standard hormonal management , include antiandrogen withdrawal Patients must continue primary hormonal therapy study treatment Regional distant metastasis Prostatespecific antigen &gt; 5 ng/mL No brain metastasis PATIENT CHARACTERISTICS : Age 18 100 Performance status ECOG 03 Life expectancy Not specify Hematopoietic Adequate hematologic function Hepatic Adequate hepatic function Renal Adequate renal function No calciumsalt kidney stone within past 5 year No hypercalcemia Cardiovascular Adequate cardiac function No significant cardiac disease No atrial fibrillation Other Fertile patient must use effective barrier contraception 2 month completion study treatment No serious medical illness No active malignancy except nonmelanoma skin cancer PRIOR CONCURRENT THERAPY : Biologic therapy More 28 day since prior biologic therapy Chemotherapy No prior chemotherapy Endocrine therapy See Disease Characteristics Radiotherapy No prior strontium chloride Sr 89 More 28 day since prior radiotherapy More 56 day since prior samarium Sm 153 lexidronam pentasodium Surgery Prior prostatectomy and/or orchiectomy allow Other More 28 day since prior investigational therapy</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>recurrent prostate cancer</keyword>
	<keyword>stage IV prostate cancer</keyword>
</DOC>